Atezolizumab plus obinutuzumab plus venetoclax in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA.Charles Herbaux,Herve Ghesquieres,Reda Bouabdallah,Stephanie Guidez,Emmanuel Gyan,Remi Gressin,Nadine Morineau,Loic Ysebaert,Steven Le Gouill,Camille Laurent,Herve Tilly,Roch Houot,Gandhi Damaj,David Sibon,Pierre Feugier,Catherine Thieblemont,Corinne Haioun, Karine Tarte,Franck Morschhauser,Guillaume CartronJOURNAL OF CLINICAL ONCOLOGY(2021)引用 3|浏览9暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要